MicroRNA expression in chronic Hepatitis C patients treated with combined pegylated interferon alpha and ribavirin therapy
El-abd, A., El-sadek, M., Ahmed, I., Mohammed, S., El-sayed, H. (2016). MicroRNA expression in chronic Hepatitis C patients treated with combined pegylated interferon alpha and ribavirin therapy. EKB Journal Management System, 36(1), 42-52. doi: 10.21608/besps.2016.8644
Awad El-abd; Magdi El-sadek; Inas A. Ahmed; Shuzan Ali Mohammed; Hend El-sayed. "MicroRNA expression in chronic Hepatitis C patients treated with combined pegylated interferon alpha and ribavirin therapy". EKB Journal Management System, 36, 1, 2016, 42-52. doi: 10.21608/besps.2016.8644
El-abd, A., El-sadek, M., Ahmed, I., Mohammed, S., El-sayed, H. (2016). 'MicroRNA expression in chronic Hepatitis C patients treated with combined pegylated interferon alpha and ribavirin therapy', EKB Journal Management System, 36(1), pp. 42-52. doi: 10.21608/besps.2016.8644
El-abd, A., El-sadek, M., Ahmed, I., Mohammed, S., El-sayed, H. MicroRNA expression in chronic Hepatitis C patients treated with combined pegylated interferon alpha and ribavirin therapy. EKB Journal Management System, 2016; 36(1): 42-52. doi: 10.21608/besps.2016.8644

MicroRNA expression in chronic Hepatitis C patients treated with combined pegylated interferon alpha and ribavirin therapy

Bulletin of Egyptian Society for Physiological Sciences
Article 5, Volume 36, Issue 1, June 2016, Page 42-52  XML PDF (484.42 K)
Document Type: Original Article
DOI: 10.21608/besps.2016.8644
View on SCiNiTO View on SCiNiTO
Authors
Awad El-abd1; Magdi El-sadek2; Inas A. Ahmed email 3; Shuzan Ali Mohammed4; Hend El-sayed5
1Departments of Medical Biochemistry,and Biochemical Endocrinology Unit, Faculty of Medicine, Benha University, Egypt
2Hepatology, Gastroenterology and Infectious Diseases,Faculty of Medicine, Benha University, Egypt.
3Department of Medical Biochemistry, Molecular Biology and Biotechnology Unit, Faculty of Medicine, Benha University, Al Qalyubia, Egypt
4Department of Medical Biochemistry, Molecular Biology and Biotechnology Unit, Faculty of Medicine, Benha University, Al Qalyubia, Egypt.
5Departments of Medical Biochemistry,Faculty of Medicine, Benha University, Egypt.
Abstract
The role of microRNAs (miRNA) in many diseases, including chronic hepatitis, represents an interesting research field. The current work aimed to study the effect of combination therapy (pegylated interferon alpha-2b plus ribavirin) on microRNA-128 (miR-128) and microRNA-296 (miR-296-5p) expression in patients with chronic hepatitis C. Also, we aimed to investigate the potential value of both types of microRNAs in differentiation between responders and non-responders either in the pre-treatment or post-treatment groups. Sixteen patients with chronic hepatitis C were compared to 10 healthy, age and sex matched controls. Venous blood samples were withdrawn before initiation of combination therapy and 12 weeks later and qPCR was used for gene expression assays. Comparison of pre-treatment group to the control group showed significant miR-128 down-regulation, while miR-296-5p showed a non-significant downregulation. Regarding post-treatment group, there was non-significant upregulation of miR-128, while miR-296-5p was significantly downregulated compared to either pre-treatment group or the control group. Comparative studies of miR-128 and miR-296-5p in responders versus non-responders showed non-significant fold change either in the pre- or post-treatment groups. It could be concluded that chronic hepatitis C as well as the combination therapy modulate miR-128/296 expression. Until now, miRNAs studied were not useful indicators to differentiate between responders and non-responders to combination therapy either in pre- or post-treatment group.
Keywords
miRNA; Chronic HCV; Combination therapy
Statistics
Article View: 272
PDF Download: 231